Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Pharming Group N.V.NASDAQ: PHAR

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA turns positive

Q1 FY2026 EBITDA was $1.06M, compared with -$4.11M a year earlier. Trailing-twelve-month EBITDA was $39.48M. Over 3 fiscal years it compounded at -1.9% a year.

Context

  • EBITDA amounted to 8.4% of revenue in FY2025, up 2.9 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $53.04M (+67.3%) for the fiscal year ending Dec 2026, a slowdown from the +87.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.06M-79.7% QoQ
Last fiscal yearDec 2025
$31.7M+87.7% YoY
LTMMar 2026
$39.48M+82.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+125.8%+23.3%-102.5 pp
1 year+87.7%+67.3%-20.3 pp
3-year CAGR-1.9%+34.8%+36.7 pp
5-year CAGR+18.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
31.7M USD
Year-over-year change
+87.7%
4-year CAGR
-13.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +82.4% is the highest of 9, against a peer median of -138.0%.
  • EBITDA amounts to 10.7% of revenue for PHAR, versus a peer median of 319.0%.
PHAR Competitors
EBITDA for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHARPharming Group N.V.LTM Mar 2026$39.48M USD+82.4%-1.9%10.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M USD——8478.5%
STOKStoke Therapeutics, Inc.LTM Mar 2026-$164.11M USD-405.9%—511.5%
PHVSPharvaris N.V.LTM Sep 2026-€184.94M EUR-15.5%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$194.47M USD+21.0%——
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-$302.96M USD-577.6%—32.2%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$384.61M USD+25.4%—581.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$473.54M USD-208.3%—49.3%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$81.69B USD-10676.6%+29.2%8.0%
Peer median (excluding PHAR) —-138.0%+29.2%319.0%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.